Anti–Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients

Arthritis and Rheumatology

Volumn 69, Issue 3, 2017, Pages 668-675

  Calvo Río, Vanesa ^a   Santos Gómez, Montserrat ^a   Calvo, Inmaculada ^b   González Fernández, M Isabel ^b   López Montesinos, Berta ^b   Mesquida, Marina ^c   Adán, Alfredo ^c   Hernández, María Victoria ^c   Maíz, Olga ^d   Atanes, Antonio ^e   Bravo, Beatriz ^f   Modesto, Consuelo ^g   Díaz Cordovés, Gisela ^h   Palmou Fontana, Natalia ^a   Loricera, Javier ^a   Gonzalez Vela M C ^a   Demetrio Pablo, Rosalía ^a   Hernandez J L ^a   González Gay, Miguel A ^a   Blanco, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL DONOSTIA   (Spain)

^e UNIVERSITY OF A CORUÑA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANAKINRA; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; AMBLYOPIA; ANEMIA; ANTERIOR EYE CHAMBER; ARTICLE; AUTOIMMUNE DISEASE; BEST CORRECTED VISUAL ACUITY; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EYE SYNECHIA; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMPETIGO BULLOSA; JUVENILE RHEUMATOID ARTHRITIS; KERATOPATHY; MALE; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; UVEITIS; VIRAL CONJUNCTIVITIS; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHILD; CLINICAL TRIAL; COMPLICATION; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; CHILD; FEMALE; HUMANS; MALE; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 85014062978     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39940     Document Type: Article

References (51)

1. Rabinovich CE. Use of tumor necrosis factor inhibitors in uveitis. Curr Opin Rheumatol 2007;19:482–6.
2. Foeldvari I. Ocular involvement in juvenile idiopathic arthritis: classification and treatment. Clin Rev Allergy Immunol 2015;49:271–7.
3. Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, et al. Patients with antinuclear antibody–positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005;52:826–32.
4. Kotaniemi K, Savolainen A, Karma A, Aho K. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 2003;48:489–502.
5. Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am 2012;59:301–27.
6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
7. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K, German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 2007;46:1015–9.
8. Vidqvist KL, Malin M, Varjolahti-Lehtinen T, Korpela MM. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology (Oxford) 2013;52:1999–2003.
9. Zulian F, Martini G, Falcini F, Gerloni V, Zannin ME, Pinello L, et al. Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol 2002;29:2446–53.
10. Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis. Pediatr Rheumatol Online J 2015;13:19.
11. Paroli MP, Spinucci G, Fabiani C, Pivetti-Pezzi P. Retinal complications of juvenile idiopathic arthritis-related uveitis: a microperimetry and optical coherence tomography study. Ocul Immunol Inflamm 2010;18:54–9.
12. Kesen MR, Setlur V, Goldstein DA. Juvenile idiopathic arthritis-related uveitis. Int Ophthalmol Clin 2008;48:21–38.
13. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 2003;14:395–8.
14. Berk AT, Kocak N, Unsal E. Uveitis in juvenile arthritis. Ocul Immunol Inflamm 2001;9:243–51.
15. García-De-Vicuña C, Díaz-Llopis M, Salom D, Bou R, Díaz-Cascajosa J, Cordero-Coma M, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm 2013;2013:560632.
16. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J 2014;12:13.
17. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 2007;17:743–8.
18. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121:785–96.
19. Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 2012;39:1294–5.
20. Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013;251:2627–32.
21. Adán A, Mesquida M, Llorenc V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 2014;252:163–4.
22. Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm 2014;22:155–7.
23. Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford) 2014;53:2223–31.
24. Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, Mesquida M, Adan AM, Herreras JM, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum 2015;45:361–8.
25. Calvo-Río V, de la Hera D, Blanco R, Beltrán-Catalán E, Loricera J, Cañal J, et al. Golimumab in uveitis previously treated with other anti-TNF-α drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol 2014;32:864–8.
26. Calvo-Río V, de la Hera D, Beltrán-Catalán E, Blanco R, Hernandez M, Martínez-Costa L, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol 2014;32 Suppl 84:S54–7.
27. Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. Clin Exp Rheumatol 2016;34 Suppl 102:34–40.
28. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis: multicenter study of 15 patients. Semin Arthritis Rheum 2016;46:95–101.
29. Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm 2008;16:1–2.
30. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509–16.
31. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467–71.
32. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373–80.
33. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology 1997;104:236–44.
34. Chalom EC, Goldsmith DP, Koehler MA, Bittar B, Rose CD, Ostrov BE, et al. Prevalence and outcome of uveitis in a regional cohort of patients with juvenile rheumatoid arthritis. J Rheumatol 1997;24:2031–4.
35. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002;86:51–6.
36. Hacker NM, Demer JL. Chorioretinitis as a complication of pauciarticular juvenile rheumatoid arthritis. J Pediatr Ophthalmol Strabismus 2005;42:183–4.
37. Paroli MP, Fabiani C, Spinucci G, Abicca I, Sapia A, Spadea L. Severe macular edema in patients with juvenile idiopathic arthritis-related uveitis. Case Rep Ophthalmol Med 2013. E-pub ahead of print.
38. Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol 1977;95:1794–7.
39. Nguyen QD, Foster CS. Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis. JAMA 1998;280:1133–4.
40. Kanski JJ. Juvenile arthritis and uveitis. Surv Ophthalmol 1990;34:253–67.
41. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91:180–4.
42. Chang PY, Giuliari GP, Shaikh M, Thakuria P, Makhoul D, Foster CS. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond) 2011;25:427–35.
43. Ravelli A, Moretti C, Temporini F, Rossi F, Magni-Manzoni S, Pistorio A, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:569–72.
44. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;11:2317–23.
45. Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis–associated uveitis: two new cases. Comment on the article by Zulian et al [letter]. Arthritis Care Res (Hoboken) 2011;63:307–8.
46. Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249:297–300.
47. Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015;42:706–11.
48. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011;50:1390–4.
49. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 2011;11:35–9.
50. Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016;100:782–6.
51. Suhler EB, Giles TR, Lin P, Shifera AS, Rosenbaum JT. An open-label trial to assess the efficacy and safety of tocilizumab in the management of juvenile idiopathic arthritis-associated uveitis: preliminary results [abstract]. Invest Ophthalmol Vis Sci 2015;56:860.